Midostaurin-associated perimyocarditis: a case report of severe cardiotoxicity of novel targeted treatments for acute myeloid leukaemia and review of the literature
In addition to the most frequently reported non-cardiac adverse effects of midostaurin, serious cardiotoxic complications appear to occur and may require discontinuation of therapy. This case highlights the importance of interdisciplinary work-up of a cardio-oncology pathway even in presumably low-risk patients and particularly in the context of rare cases of cardiotoxicity in novel cancer treatments.
Authors
- Lenhard Pennig (ORCID: https://orcid.org/0000-0002-6606-9313)
- Roman Pfister (ORCID: https://orcid.org/0000-0002-4358-5008)
- Jannik Stemler (ORCID: https://orcid.org/0000-0001-9152-2469)
- Oliver A. Cornely (ORCID: https://orcid.org/0000-0001-9599-3137)
- Alev Kalkan
Institutions
- University of Cologne (DE)
- German Center for Infection Research (DE)
- Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (DE)
- University Hospital Cologne (DE)
Publication Details
- Journal
- European Heart Journal - Case Reports
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1093/ehjcr/ytaf044
- Citations
- 1
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 1.39